肾糖康合剂联合西药治疗早期糖尿病肾病的临床研究

目的观察肾糖康合剂对早期糖尿病肾病(diabetic nephropathy,DN)的临床疗效。方法将符合纳入标准的40例早期DN患者随机分为治疗组和对照组各20例,2组均予控制饮食、降糖等基础治疗,同时给予福辛普利每日1次,连服2月;治疗组在此基础上口服肾糖康合剂,每日1剂,每次300 ml,早晚各服1次,连服2月。结果治疗组尿微量白蛋白/肌酐比值(Alb/Cr)和超敏C反应蛋白(hsCRP)水平显著优于对照组,二者具有统计学差异。结论肾糖康合剂可以改善早期DN患者临床症状,减少尿微量白蛋白排泄,降低hsCRP从而改善慢性炎症。

Clinical study of renal glucose kang mixture combined with western medicine in the treatment of early diabetic nephropathy

Objective To observe the clinical effect of renal glucose kang mixture on early diabetic nephropathy （DN）. Methods A total of 40 patients with early DN were randomly divided into treatment group（n=20） and control group（ n= 20）. Two groups were given the diet and hypoglycemie therapy, meanwhile they were given Fosinopril sodium tablets one time a day, continuously for two months ; The treatment group was given the oral renal glucose kang mixture with one agent a day and 300 ml each time, continuously for two months. Results After the treatment, the outcome of treat- ment group in reducing urinary mieroalbumin/ereatinine and high sensitive C reactive protein was statistically better than that of control group. Conclusions renal glucose kang mixture can improve the clinical symptoms of patients with early DN, through reducing urinary microalbumin/ereatinine and lowering high sensitivity C reactive protein that is related to clinical inflammation.